CTRI/2018/11/016419已完成2 期
A multicentre single blind randomised controlled Phase-II/III study to evaluate immunogenicity and safety of single intramuscular dose of Biological Eâ??s Vi-capsular Polysaccharide-CRM197 Conjugate Typhoid Vaccine in healthy infants, children and adults in comparison with a licensed comparator. - None
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 595
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy subjects of either gender between >=6 months to <64 years of age at the time of vaccination
- •2. Subject or Subjectâ??s Parent(s) or LAR who after the nature of the study has been explained to them, have given written consent according to local regulatory requirements.
- •3. Subject or Subjectâ??s Parent(s) or LARâ??s ability to understand information relevant to participation in the study and abide with the requirements of the subject diary and other study procedures;
- •4. Individuals in good health as determined by the outcome of medical history, physical examination based on clinical judgment of the investigator.
- •5. Negative to urine pregnancy test for female subjects of childbearing potential. Female of childbearing potential is defined as a pre-menopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 year earlier, or (3) total hysterectomy.
排除标准
- •1. Individuals who have a previously ascertained or suspected disease caused by Salmonella typhi;
- •2. Individuals who have history of household contact with/and or intimate exposure to an individual with laboratory confirmed S. typhi;
- •3. Individuals who have previously received any vaccines against typhoid fever (either oral live attenuated or injectable vaccines);
- •4. Individuals with body temperature >=100.4°F (>=38.0°C) within 3 days of intended study immunization;
- •5. Individuals with any serious chronic or progressive disease according to judgment of the investigator (e.g., neurological, neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease);
- •6. Subject or Subjectâ??s Parent(s) or LAR unwillingness or inability to understand and follow required study procedures, keep appointments, or are planning to relocate during the study period;
- •7. Individuals with history of any illness or any laboratory abnormality that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study;
- •8. Subject with suspected or known history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within the previous 30 days;
- •9. Subject with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time or history of receipt of anti-coagulants in the past 3 weeks;
- •10. History of allergy or allergic reaction to any vaccine-related component;
- •11. Individuals participating in any other clinical trial within 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study;
- •12. Women who are pregnant or breast-feeding or of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Female of childbearing potential or age is defined as a pre-menopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 year earlier, or (3) total hysterectomy.
- •13. Any other reason that in the opinion of the investigator may interfere with the evaluation required by the study objectives.
研究者
相似试验
已完成
不适用
A randomised controlled single-blind multi-centre study to investigate the induction of ALUminium contact allergy in children/adults receiving hyposensitisation therapy due to allergic diseaseSkin and Connective Tissue DiseasesAllergyISRCTN57796160Malmö University Hospital (Sweden)500
尚未招募
不适用
A randomised controlled single blinded multicentre trial of polyethylene glycol sealant to the staple line vs staple line alone in distal pancreatectomy.ACTRN12620001336976Institute for Breathing and Sleep80
进行中（未招募）
不适用
A randomized controlled single blind multicenter study to investigate the induction of aluminium contact allergy in children/adults receiving hyposensitisation therapy due to allergic disease.Children and adults will answer questionnaires and be tested epicutaneously to detect aluminium hypersensitivity and possible risk factors associated with the development of contact allergy to aluminium due to hyposensitisation therapyThe development of contact allergy to aluminium during hyposensitization therapy.EUCTR2007-003000-35-SEDepartment of Occupational and Environmental Dermatology, Malmö University Hospital500
已完成
不适用
Randomized controlled trial to compare low dose oral sulfate solution and polyethylene glycol in adultsKCT0001651Kangbuk Samsung Medical Center210
已完成
不适用
Inko-Outside multicentre, controlled, randomised, blinded study for the treatment of stress urinary incontinenceStress urinary incontinenceUrological and Genital DiseasesOther disorders of urinary systemISRCTN32312996orth Georgia College and State University (USA)243